Taiwan-based Bora Pharmaceuticals Co. and Celltrion Asia Pacific, a subsidiary of South Korea-based Celltrion Group Inc, have announced their partnership to contract manufacture and commercialise a range of oral dosage form drugs (OSD) across the Asia Pacific (APAC) region.
The range of oral dosage form products will be manufactured at Bora’s Zhunan Site, which is one of the largest US FDA and MHRA-approved pharmaceutical production facilities in Taiwan. The site has an outstanding compliance record across global regulatory authorities.
The manufactured batches will be used to support Celltrion’s regulatory filings for approval in seven countries, and Bora will further support Celltrion to commercialise the products immediately upon approval by utilising its cutting-edge manufacturing capabilities in complex oral dosage form and superior total-solution services.
